文献速递乳腺癌

RAD51 foci作为gBRCA突变乳腺癌同源重组修复功能及PARP抑制剂耐药的生物标志物

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
PubMed 文献 · Ann Oncol · 2018-01-01

该研究在gBRCA1患者来源异种移植瘤(PDX)及gBRCA1/2患者回顾性样本中,评估RAD51核 foci作为同源重组修复(HRR)功能替代标志物与PARP抑制剂(PARPi)敏感性的关系。结果显示RAD51 foci是原发或获得性PARPi耐药PDX及患者样本的唯一共同特征,低RAD51与PARPi客观缓解相关。RAD51 foci检测有望用于临床筛选PARPi治疗获益人群。

要点

  • RAD51 foci是HRR功能的替代标志物,在PARPi耐药PDX和患者样本中共同存在。
  • 低RAD51与gBRCA1/2肿瘤对PARPi的客观缓解相关。
  • 在PDX中,PARPi联合ATM抑制剂可逆转PARPi耐药。

核心结论

  • gBRCA肿瘤中RAD51 foci检测与PARPi耐药相关,无论HRR功能恢复的潜在机制如何。
  • RAD51 foci是有前景的临床生物标志物,可更好筛选PARPi治疗患者。
  • 研究支持PARPi联合ATM抑制剂等联合方案的临床开发。

研究设计与样本

  • 研究使用gBRCA1患者来源肿瘤异种移植瘤(PDX),对PARPi反应存在差异。
  • 分析包括外显子测序和DNA损伤应答蛋白免疫染色以功能评估HRR。
  • 结果在接受PARPi治疗的gBRCA1/2癌症患者回顾性样本集中验证。

主要发现

  • RAD51核 foci是PARPi原发或获得性耐药的PDX和患者样本中唯一的共同特征。
  • 低RAD51与PARPi客观缓解相关。
  • 在PARPi耐药的gBRCA1 PDX中,60%模型存在BRCA1亚效蛋白,20%存在TP53BP1缺失,一个样本存在RAD51扩增,且互不排斥。
  • 三个PARPi耐药的gBRCA2肿瘤中,一个通过外显子测序显示BRCA2恢复。
  • 在PDX中,PARPi联合ATM抑制剂可逆转PARPi耐药。

临床怎么用

  • RAD51 foci检测可用于gBRCA突变肿瘤患者,以预测PARPi敏感性和耐药。
  • 对PARPi耐药患者,可考虑联合ATM抑制剂的治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: BRCA1 and BRCA2 (BRCA1/2)-deficient tumors display impaired homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents or to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). Their efficacy in germline BRCA1/2 (gBRCA1/2)-mutated metastatic breast cancers has been recently confirmed in clinical trials. Numerous mechanisms of PARPi resistance have been described, whose clinical relevance in gBRCA-mutated breast cancer is unknown. This highlights the need to identify functional biomarkers to better predict PARPi sensitivity. PATIENTS AND METHODS: We investigated the in vivo mechanisms of PARPi resistance in gBRCA1 patient-derived tumor xenografts (PDXs) exhibiting differential response to PARPi. Analysis included exome sequencing and immunostaining of DNA damage response proteins to functionally evaluate HRR. Findings were validated in a retrospective sample set from gBRCA1/2-cancer patients treated with PARPi. RESULTS: RAD51 nuclear foci, a surrogate marker of HRR functionality, were the only common feature in PDX and patient samples with primary or acquired PARPi resistance. Consistently, low RAD51 was associated with objective response to PARPi. Evaluation of the RAD51 biomarker in untreated tumors was feasible due to endogenous DNA damage. In PARPi-resistant gBRCA1 PDXs, genetic analysis found no in-frame secondary mutations, but BRCA1 hypomorphic proteins in 60% of the models, TP53BP1-loss in 20% and RAD51-amplification in one sample, none mutually exclusive. Conversely, one of three PARPi-resistant gBRCA2 tumors displayed BRCA2 restoration by exome sequencing. In PDXs, PARPi resistance could be reverted upon combination of a PARPi with an ataxia-telangiectasia mutated (ATM) inhibitor. CONCLUSION: Detection of RAD51 foci in gBRCA tumors correlates with PARPi resistance regardless of the underlying mechanism restoring HRR function. This is a promising biomarker to be used in the clinic to better select patients for PARPi therapy. Our study also supports the clinical development of PARPi combinations such as those with ATM inhibitors.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Cruz C, Castroviejo-Bermejo M, Gutiérrez-Enríquez S, et al. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol. 2018. PMID: 29635390. doi:10.1093/annonc/mdy099

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。